OncoMatch/Clinical Trials/NCT06128148

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

Is NCT06128148 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for protein kinase inhibitors.

Phase 1RecruitingGuangzhou JOYO Pharma Co., LtdNCT06128148Data as of Jun 2026Location: China

Treatment: JYP0322 50 mg qd · JYP0322 100 mg qd · JYP0322 200 mg qd · JYP0322 100 mg bid · JYP0322 150 mg bid · JYP0322 200 mg bid · JYP0322 150mg tid — An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

JYP0322 50 mg qdJYP0322 100 mg qdJYP0322 200 mg qdJYP0322 100 mg bidJYP0322 150 mg bidJYP0322 200 mg bidJYP0322 150mg tid

Biomarker criteria

Required: ROS1 fusion

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06128148 currently recruiting?

Yes, this trial is currently recruiting patients.

Does this trial require ROS1?

Yes, ROS1 fusion is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify